Doctors discover 58 new drug and supplement combinations you must NEVER take together - they could have deadly consequences for millions of Americans
The study suggests at least 20million Americans who rely on heart disease medications like the blood thinner warfarin could be unwittingly putting themselves at risk. (Source: the Mail online | Health)
Source: the Mail online | Health - February 20, 2024 Category: Consumer Health News Source Type: news
Warfarin Cuts Mortality, Thromboembolism After Valve Replacement
THURSDAY, Jan. 4, 2024 -- Warfarin use after bioprosthetic surgical aortic valve replacement (sAVR) is associated with lower all-cause mortality and a decreased risk for thromboembolism compared with not receiving warfarin, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 4, 2024 Category: Pharmaceuticals Source Type: news
Warfarin Tied to Benefit After SAVR Warfarin Tied to Benefit After SAVR
Treatment with warfarin early after bioprosthetic surgical aortic valve replacement is associated with lower mortality and thromboembolism risk but increased major bleeding events.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - December 29, 2023 Category: Cardiology Tags: Cardiology Source Type: news
Use of anticoagulant drug after aortic valve replacement lowers mortality risk, Mayo Clinic study finds
ROCHESTER, Minn. — Patients who received the anticoagulant drug warfarin after bioprosthetic aortic valve replacement had lower incidence of mortality and a decreased risk of blood clots, according to a retrospective study published in Mayo Clinic Proceedings. The use of bioprosthetic aortic valve replacement has increased significantly during the past decade. Among its advantages is that most patients can avoid warfarin for anticoagulation treatment. Even so, research has been conflicting on whether patients would benefit… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - December 7, 2023 Category: Databases & Libraries Source Type: news
No Aspirin Needed After LVAD, ARIES-HM3 Trial Says
(MedPage Today) -- PHILADELPHIA -- Dropping aspirin from the antithrombotic regimen after HeartMate 3 left ventricular assist device (LVAD) implantation appeared safer than the usual combination approach in the ARIES-HM3 trial.
Atop warfarin... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - November 12, 2023 Category: Cardiology Source Type: news
FDA Greenlights Balfaxar for Warfarin Reversal FDA Greenlights Balfaxar for Warfarin Reversal
Balfaxar helps restore blood coagulation by replenishing the levels of clotting factors.Medscape Medical News (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - October 3, 2023 Category: Primary Care Tags: Emergency Medicine Source Type: news
How To Avoid China ’ s Medicine Monopoly
I want to share a shocking statistic with you…
Around 80% of all the pharmaceuticals sold in America — both prescription and over-the-counter — are manufactured in China.
I’m talking about drugs for Parkinson’s and Alzheimer’s, blood pressure and blood thinners, diuretics, aspirin, antibiotics, and a big chunk of the world’s insulin and diabetes drugs — just to name a few.1
We don’t even make penicillin anymore. The last penicillin plant in the U.S. closed its doors in 2004.
Americans who rely on medicine are now almost entirely at the mercy of a country whose relations with the U.S. have become more ...
Source: Al Sears, MD Natural Remedies - September 19, 2023 Category: Complementary Medicine Authors: Jacob Tags: Health Source Type: news
DOACs Reduce Dementia Risk Versus Warfarin in A-Fib
THURSDAY, Sept. 7, 2023 -- For patients with atrial fibrillation (AF), the use of direct-acting oral anticoagulants (DOACs) significantly reduces dementia risk compared with warfarin, according to a systematic review and meta-analysis published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 7, 2023 Category: Pharmaceuticals Source Type: news
Apixaban Has Lower Bleeding Risk for Initial Anticoagulation for Venous Thromboembolism
TUESDAY, Sept. 5, 2023 -- Apixaban has a lower bleeding risk than warfarin or rivaroxaban during initial treatment for patients with venous thromboembolism (VTE), according to a study published online Aug. 28 in the Journal of Internal... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 5, 2023 Category: Pharmaceuticals Source Type: news
Rush to DOACs Spells Trouble for Frail Warfarin Users
(MedPage Today) -- AMSTERDAM -- Best let frail older people who are stable on international normalized ratio (INR)-guided vitamin K antagonist (VKA) management stay on it instead of switching to a direct oral anticoagulant (DOAC or NOAC), the... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - August 28, 2023 Category: Cardiology Source Type: news
Prolonged Direct Oral Anticoagulants Beneficial for Preventing Recurrent VTE
MONDAY, Aug. 21, 2023 -- For patients with venous thromboembolism (VTE) continuing warfarin or direct oral anticoagulants (DOACs) beyond six months, the risk for recurrent VTE is lower with DOACs, according to a study published online Aug. 15 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 21, 2023 Category: Pharmaceuticals Source Type: news
FDA Approves Balfaxar (prothrombin complex concentrate, human-lans) for Warfarin Reversal in Urgent Surgery & Invasive Procedures
PARAMUS, N.J., July 26, 2023 /PRNewswire/ -- Octapharma USA today announced that Balfaxar® (prothrombin complex concentrate, human-lans; marketed in Europe and Canada as octaplex®) has received U.S. Food and Drug Administration (FDA)... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 26, 2023 Category: Drugs & Pharmacology Source Type: news
Risk for Single-Positive LAC Results With Anticoagulants Risk for Single-Positive LAC Results With Anticoagulants
Should lupus anticoagulant testing be avoided in patients receiving anticoagulation with DOACs or warfarin, due to potential false-positive results?American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 30, 2023 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news
Standard-Dose DOAC Better for Kidney-Impaired Patients
(MedPage Today) -- Standard-dose direct oral anticoagulants (DOACs) safely bested both lower doses and warfarin among patients with kidney dysfunction in subgroup analysis across pivotal clinical trials in atrial fibrillation (AF).
The benefit... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 13, 2023 Category: Cardiology Source Type: news
New VOYAGER PAD Analysis Confirms Consistent Benefit of XARELTO ® (rivaroxaban) Plus Aspirin Following Lower Extremity Revascularization (LER)
TITUSVILLE, NJ, March 5, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from a new prespecified analysis from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefits of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) over standard of care (aspirin alone), demonstrating consistent benefit at 30 days, 90 days and up to three years following LER in patients with PAD. Lower extremity revascularization, also called peripheral revascularization, is a procedure that restores blood flow in blocked arteries or veins. This analysis of ...
Source: Johnson and Johnson - March 5, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
